AstraZeneca-Amgen Combination Improves Survival in Aggressive Lung Cancer

A combination of Amgen's Imdelltra and AstraZeneca's Imfinzi improved overall survival in a late-stage trial involving extensive-stage small-cell lung…

Continue in Briflio to read, react, comment, and share.